FDA-approved alkylating agents for the treatment of brain tumors
| Medication | Tumor type | Mechanism of action | Reference |
|---|---|---|---|
| Temozolomide | GBM and anaplastic astrocytoma | Alkylating agent that leads to methylation and later apoptosis of impacted cells | [6] |
| Carmustine | Glial tumors (wafers are frequently placed at the time of GBM resection as a bridge to radiation therapy) | Alkylating agent administered via intravenous injection or local implantation in wafer form | [7] |
| Lomustine | Glial and non-glial cell tumors like medulloblastoma | Nitrosourea works as an alkylating agent | [8, 9] |
BLW: Conceptualization, Supervision, Writing—review & editing. MM: Conceptualization, Project administration, Visualization. MS, AS and MM: Writing—original draft, Writing—review & editing
The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of Defense, or the U.S. Government.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.